The ESMO Preceptorship on Metastatic Bladder and Kidney Cancer 2026 is a two-day advanced educational course designed to equip oncologists with a comprehensive understanding of the latest standards in managing metastatic bladder cancer and metastatic kidney cancer. This program provides in-depth education on current treatment guidelines, molecular pathology, and emerging therapeutic targets shaping the future of urothelial and renal cancer care.

Event Details

• Dates: February 18–19, 2026

• Location: Lugano, Switzerland

• Accreditation: ESMO-MORA Category 1 points

• Application Deadline: December 11, 2025

• Benefits: Complimentary course registration and accommodation for accepted participants

What Participants Will Learn

• Up-to-date standards of care for metastatic bladder and kidney cancer

• Interpretation of molecular diagnostics and their role in treatment selection

• Current and emerging systemic therapies, including immunotherapy and targeted agents

• Case-based learning and discussions with leading experts in genitourinary oncology

Why Attend This ESMO Preceptorship

• Gain high-quality, evidence-based education led by international oncology specialists

• Enhance clinical decision-making through expert-led case reviews

• Strengthen your understanding of molecular mechanisms and personalized treatment strategies

• Connect with peers and expand your professional oncology network

The ESMO Preceptorship on Metastatic Bladder and Kidney Cancer 2026 – Lugano is an essential learning opportunity for oncologists looking to advance their expertise in metastatic genitourinary cancers and stay at the forefront of evolving cancer therapeutics.